Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells

被引:21
作者
Liu, Zuqiang [1 ]
Noh, Hae S. [1 ]
Chen, Janet [1 ]
Kim, Jin H. [1 ]
Falo, Louis D. [1 ,3 ]
You, Zhaoyang [1 ,2 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA
基金
美国国家卫生研究院;
关键词
D O I
10.4049/jimmunol.181.6.4363
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Administration of anti-CD25 mAb before an aggressive murine breast tumor inoculation provoked effective antitumor immunity. Compared with CD4(+) T cells purified from anti-CD25 mAb-pretreated mice that did not reject tumor, CD4(+) T cells purified from anti-CD25 mAb-pretreated mice that rejected tumor stimulated by dendritic cells (DCs) produced more IFN-gamma and IL-2, and less IL-17 in vitro, and ignited protective antitumor immunity in vivo in an adoptive transfer model. Tumor Ag-loaded DCs activated naive CD8(+) T cells in the presence of these CD4+ T cells in vitro. Tumor Ag and adoptively transferred CD4+ T cells were both required for inducing a long-term tumor-specific IFN-gamma-producing cellular response and potent protective antitumor activity. Although adoptively transferred CD4+ T cells ignited effective tumor-specific antitumor immunity in wild-type mice, they failed to do so in endogenous NK cell-depleted, Gr-1(+) cell-depleted, CD40(-/-), CD11c(+) DC-depleted, B cell(-/-), CD8+ T cell-depleted, or IFN-gamma(-/-) mice. Collectively, the data suggest that adoptively transferred CD4(+) T cells orchestrate both endogenous innate and adaptive immunity to generate effective tumor-specific long-term protective antitumor immunity. The data also demonstrate the pivotal role of endogenous DCs in the tumor-specific protection ignited by adoptively transferred CD4+ T cells. Thus, these findings highlight the importance of adoptively transferred CD4(+) T cells, as well as host immune components, in generating effective tumor-specific long-term antitumor activity.
引用
收藏
页码:4363 / 4370
页数:8
相关论文
共 56 条
[1]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[2]   The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines [J].
Assudani, Deepak P. ;
Horton, Roger B. V. ;
Mathieu, Morgan G. ;
McArdle, Stephanie E. B. ;
Rees, Robert C. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (01) :70-80
[3]   IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen [J].
Beatty, GL ;
Paterson, Y .
JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5502-5508
[4]   IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy [J].
Berner, Vanessa ;
Liu, Haiyan ;
Zhou, Qing ;
Alderson, Kory L. ;
Sun, Kai ;
Weiss, Jonathan M. ;
Back, Timothy C. ;
Longo, Dan L. ;
Blazar, Bruce R. ;
Wiltrout, Robert H. ;
Welniak, Lisbeth A. ;
Redelman, Doug ;
Murphy, William J. .
NATURE MEDICINE, 2007, 13 (03) :354-360
[5]   Helping the CD8+ T-cell response [J].
Bevan, MJ .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (08) :595-602
[6]   CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination [J].
Casares, N ;
Arribillaga, L ;
Sarobe, P ;
Dotor, J ;
de Cerio, ALD ;
Melero, I ;
Prieto, J ;
Borrás-Cuesta, F ;
Lasarte, JJ .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5931-5939
[7]   An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy [J].
Chamoto, K ;
Wakita, D ;
Narita, Y ;
Zhang, Y ;
Noguchi, D ;
Ohnishi, H ;
Iguchi, T ;
Sakai, T ;
Ikeda, H ;
Nishimura, T .
CANCER RESEARCH, 2006, 66 (03) :1809-1817
[8]   Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells [J].
Chamoto, K ;
Tsuji, T ;
Funamoto, H ;
Kosaka, A ;
Matsuzaki, J ;
Sato, T ;
Abe, H ;
Fujio, K ;
Yamamoto, K ;
Kitamura, T ;
Takeshima, T ;
Togashi, Y ;
Nishimura, T .
CANCER RESEARCH, 2004, 64 (01) :386-390
[9]   Primary T cell expansion and requires antigen presentation differentiation in vivo by B cells [J].
Crawford, Alison ;
MacLeod, Megan ;
Schumacher, Ton ;
Corlett, Louise ;
Gray, David .
JOURNAL OF IMMUNOLOGY, 2006, 176 (06) :3498-3506
[10]   CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy [J].
Diehl, L ;
den Boer, AT ;
Schoenberger, SP ;
van der Voort, EIH ;
Schumacher, TNM ;
Melief, CJM ;
Offringa, R ;
Toes, REM .
NATURE MEDICINE, 1999, 5 (07) :774-779